IL-17 promoted metastasis of non-small-cell lung cancer cells

被引:107
|
作者
Li, Qinchuan [1 ]
Han, Yang [2 ]
Fei, Guangru [3 ]
Guo, Zhongliang [3 ]
Ren, Tao [3 ]
Liu, Zhongmin [1 ]
机构
[1] Tongji Univ, Sch Med, East Hosp, Dept Cardiothorac Surg, Shanghai 200120, Peoples R China
[2] Tongji Univ, Sch Med, East Hosp, Dept Pathol, Shanghai 200120, Peoples R China
[3] Tongji Univ, Sch Med, East Hosp, Dept Resp Med, Shanghai 200120, Peoples R China
基金
中国国家自然科学基金;
关键词
Lung cancer; NSCLC; Metastasis; IL-17; IL-6; TUMOR-GROWTH; INTERLEUKIN-17; BREAST; MICE; ANGIOGENESIS; AUTOIMMUNITY; FIBROSARCOMA; INFLAMMATION; EXPRESSION; RESPONSES;
D O I
10.1016/j.imlet.2012.10.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Recent data suggested that IL-17 might be a pivotal cytokine involved in tumor progression of NSCLC. However, the direct effect of IL-17 on metastasis of NSCLC cells still remains intractable. In this study, we found that the metastasis of NSCLC was significantly impaired in IL-17(-/-) mice. Further, we revealed that IL-17 could directly promote the invasion of NSCLC cells both in vitro and in vivo. Furthermore, we found that IL-6-Stat3 pathway was crucial for IL-17 to enhance the invasive potential of NSCLC cells. Finally, we found that elevated expression of IL-17 in peripheral blood was associated with the TNM stage, and elevated expression of IL-17R in NSCLC cells was associated with their invasive potential in NSCLC patients. These findings could facilitate our understanding of the potential role of IL-17 in tumor biology, and provide clues for developing promising strategies against NSCLC. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:144 / 150
页数:7
相关论文
共 50 条
  • [41] Erlotinib in non-small-cell lung cancer
    Gridelli, Cesare
    Rossi, Antonio
    Malone, Paolo
    Colantuoni, Giuseppe
    Del Gaizo, Filomena
    Ferrara, Carmine
    Nicolella, Dario
    Guerriero, Ciro
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) : 2579 - 2592
  • [42] NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10
    Sun, Yingjia
    Ai, Xinghao
    Shen, Shengping
    Lu, Shun
    ONCOTARGET, 2015, 6 (10) : 8244 - 8254
  • [43] Cetuximab in non-small-cell lung cancer
    Carillio, Guido
    Montanino, Agnese
    Costanzo, Raffaele
    Sandomenico, Claudia
    Piccirillo, Maria Carmela
    Di Maio, Massimo
    Daniele, Gennaro
    Giordano, Pasqualina
    Bryce, Jane
    Normanno, Nicola
    Rocco, Gaetano
    Perrone, Francesco
    Morabito, Alessandro
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (02) : 163 - 175
  • [44] Non-small-cell lung cancer in the elderly
    Meriggi, F
    Zaniboni, A
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 57 (02) : 183 - 190
  • [45] Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations
    Liu, Fangfang
    Yuan, Xun
    Jiang, Jizong
    Chu, Qian
    IMMUNOTHERAPY, 2020, 12 (16) : 1195 - 1207
  • [46] Axitinib for the treatment of advanced non-small-cell lung cancer
    King, Judy W.
    Lee, Siow-Ming
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 765 - 773
  • [47] Serological investigation of the clinical significance of fascin in non-small-cell lung cancer
    Teng, Yu
    Xu, Shaofa
    Yue, Wentao
    Ma, Li
    Zhang, Lina
    Zhao, Xiaoting
    Guo, Yinan
    Zhang, Chunyan
    Gu, Meng
    Wang, Yue
    LUNG CANCER, 2013, 82 (02) : 346 - 352
  • [48] Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer
    Mengqin Shen
    Xiaoping Zhao
    Li Zhao
    Liang Shi
    Shuxian An
    Gang Huang
    Jianjun Liu
    Molecular Cancer, 17
  • [49] Gemcitabine: A reality in the treatment of non-small-cell lung cancer
    Rinaldi, M
    TUMORI, 1997, 83 (06) : S3 - S7
  • [50] Emerging antiangiogenic therapies for non-small-cell lung cancer
    Blakely, Collin
    Jahan, Thierry
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (10) : 1607 - 1618